Eli Lilly Strikes $2.75B Deal To Bring AI-Developed Drugs Globally - Eli Lilly (NYSE:LLY)
Published on March 29, 2026.
Eli Lilly & Co. has reportedly reached a $2.75 billion agreement to introduce AI-developed drugs from Hong Kong's Insilico Medicine to the global market. The deal began with an AI-based software licensing deal in 2023. The partnership is expected to explore new mechanisms and identify therapeutic candidates. As part of the deal, Insilic will join Lilly's Gateway Labs for biotech development.
Related Articles
Bring spring cleaning into the digital space with this iOS Cleaner Kit
A lifetime subscription to Cleaner Kit, powered by AI, allows you to declutter your iOS phone using a premium lifetime subscription, reducing storage, improving performance, and privacy.
Apple's brand-new 14- and 16-inch MacBook Pros are up to $200 off
Apple's new 14-inch MacBook Pro models are available for up to $200 off, with significant discounts including $10,000 on top, and $25,000 in designer shoes.
The World’s 100 Greatest Places of 2026
The article's full length length:.